CA2608821A1 - Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds - Google Patents

Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds Download PDF

Info

Publication number
CA2608821A1
CA2608821A1 CA002608821A CA2608821A CA2608821A1 CA 2608821 A1 CA2608821 A1 CA 2608821A1 CA 002608821 A CA002608821 A CA 002608821A CA 2608821 A CA2608821 A CA 2608821A CA 2608821 A1 CA2608821 A1 CA 2608821A1
Authority
CA
Canada
Prior art keywords
hiv
alkyl
group
pharmaceutically acceptable
antiviral compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002608821A
Other languages
English (en)
French (fr)
Inventor
Shibo Jiang
Asim Kumar Debnath
Hong Lu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York Blood Center
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2608821A1 publication Critical patent/CA2608821A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA002608821A 2005-06-15 2006-06-06 Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds Abandoned CA2608821A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69112005P 2005-06-15 2005-06-15
US60/691,120 2005-06-15
PCT/US2006/021993 WO2006138118A2 (en) 2005-06-15 2006-06-06 Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds

Publications (1)

Publication Number Publication Date
CA2608821A1 true CA2608821A1 (en) 2006-12-28

Family

ID=37570970

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002608821A Abandoned CA2608821A1 (en) 2005-06-15 2006-06-06 Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds

Country Status (5)

Country Link
US (1) US20060287319A1 (enExample)
EP (1) EP1896033A4 (enExample)
JP (1) JP2008543836A (enExample)
CA (1) CA2608821A1 (enExample)
WO (1) WO2006138118A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2007004244A0 (en) 2005-05-10 2007-12-31 Intermune Inc Method of modulating stress-activated protein kinase system
US20070099970A1 (en) * 2005-08-19 2007-05-03 Mackerell Alexander Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain
JP2011502998A (ja) * 2007-11-01 2011-01-27 ザ ユーエイビー リサーチ ファウンデイション ウイルス感染の治療および予防
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US8455516B2 (en) * 2010-01-15 2013-06-04 Touro University HIV-1 fusion inhibitors and methods
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
EP2590971A4 (en) * 2010-06-17 2014-12-10 Fuzians Biomedicals Inc COMPOUNDS SUITABLE FOR ANTIVIRAL ACTIVE SUBSTANCES, COMPOSITIONS AND METHOD OF USE THEREOF
US9023876B2 (en) * 2010-07-08 2015-05-05 Adhaere Pharmaceuticals, Inc. Compounds and methods for regulating integrins
CA2882853C (en) 2012-04-20 2021-11-23 Vineet Gupta Compounds and methods for regulating integrins
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CN103724337A (zh) * 2012-10-15 2014-04-16 南京大学 一类含萘环和噻唑啉酮结构的吡唑啉类衍生物及其制法
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
EP3837275A4 (en) 2018-06-29 2022-07-13 Fred Hutchinson Cancer Center CELL STORED BARCODED DEEP MUTATION SCANNING LIBRARIES AND THEIR USES
CN111747944B (zh) * 2020-07-13 2022-09-30 复旦大学 广谱抗包膜病毒化合物、组合物及其应用
WO2022225572A1 (en) * 2021-04-22 2022-10-27 New York Blood Center, Inc. Respiratory virus inhibitors
CN115444846A (zh) * 2022-09-01 2022-12-09 中国人民解放军军事科学院军事医学研究院 HIV-1Tat蛋白抑制剂及其应用
WO2024260445A1 (zh) * 2023-06-21 2024-12-26 上海科技大学 一种噻唑烷二酮类化合物、其药物组合物和其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL141456A0 (en) * 1998-08-21 2002-03-10 Viropharma Inc Rhodanine derivatives and pharmaceutical compositions containing the same
US20050042674A9 (en) * 2002-02-21 2005-02-24 Lin Yu Common ligand mimics: thiazolidinediones and rhodanines
US20040002526A1 (en) * 2002-04-03 2004-01-01 Cell Therapeutics, Inc. Phospholipase D inhibitors and uses thereof
AU2003294275A1 (en) * 2002-11-21 2004-06-18 New York Blood Center Compounds for inhibition of hiv infection by blocking hiv entry
DE602004025708D1 (de) * 2003-07-11 2010-04-08 Proteologics Inc Ubiquitin-ligase-hemmer und verwandte verfahren
EP1654380A4 (en) * 2003-08-14 2009-09-09 Insight Biopharmaceuticals Ltd METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING HEPARANASE ACTIVATION AND USES THEREOF
WO2005041951A2 (en) * 2003-10-28 2005-05-12 Rigel Pharmaceuticals, Inc. Rhodanine derivatives for use as antiviral agents

Also Published As

Publication number Publication date
WO2006138118B1 (en) 2007-09-20
WO2006138118A3 (en) 2007-07-26
EP1896033A4 (en) 2010-12-22
JP2008543836A (ja) 2008-12-04
US20060287319A1 (en) 2006-12-21
WO2006138118A2 (en) 2006-12-28
EP1896033A2 (en) 2008-03-12

Similar Documents

Publication Publication Date Title
Jiang et al. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion
Zhao et al. Identification of N-phenyl-N′-(2, 2, 6, 6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4
Lu et al. Development of small-molecule HIV entry inhibitors specifically targeting gp120 or gp41
US20060287319A1 (en) Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds
Schmidt et al. Small-molecule inhibitors of dengue-virus entry
US20070232684A1 (en) Compounds for inhibition of HIV infection by blocking HIV entry
Jiang et al. A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody
Liu et al. Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41
Liu et al. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120
O’Keefe et al. Analysis of the interaction between the HIV-inactivating protein cyanovirin-N and soluble forms of the envelope glycoproteins gp120 and gp41
US20090176776A1 (en) Small molecule inhibitors of hiv-1 capsid assembly
An et al. Amino acid derivatives of the (−) enantiomer of gossypol are effective fusion inhibitors of human immunodeficiency virus type 1
Urvashi et al. Development of azaindole-based frameworks as potential antiviral agents and their future perspectives
Bastian et al. Interactions of peptide triazole thiols with Env gp120 induce irreversible breakdown and inactivation of HIV-1 virions
He et al. Conserved salt bridge between the N-and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibition
Wang et al. ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation
Pan et al. Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide-sensitive and-resistant HIV type 1 strains
CN112316152B (zh) 经酸酐修饰的蛋白质抑制冠状病毒的方法
Zhao et al. XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41
Qiu et al. N-substituted pyrrole derivative 12m inhibits HIV-1 entry by targeting Gp41 of HIV-1 envelope glycoprotein
Zhang et al. Identification of an HIV-1 replication inhibitor which rescues host restriction factor APOBEC3G in Vif–APOBEC3G complex
Mediouni et al. Potent suppression of HIV-1 cell attachment by Kudzu root extract
Xu et al. Evaluation of “credit card” libraries for inhibition of HIV-1 gp41 fusogenic core formation
Pu et al. Rational design of a novel small-molecule HIV-1 inactivator targeting both gp120 and gp41 of HIV-1
Bailey et al. Disulfide sensitivity in the Env protein underlies lytic inactivation of HIV-1 by peptide triazole thiols

Legal Events

Date Code Title Description
FZDE Discontinued